Trial results for a study assessing COVID-19 testing strategies in K-12 schools were posted on ClinicalTrials.gov on 2025-07-04, revealing no statistically significant difference (p=0.25) between two compared approaches.
Background
COVID-19 has significantly impacted K-12 education, prompting the need for effective mitigation strategies to ensure the safe return to in-person learning, particularly in underserved communities. Regular screening testing has been recommended by public health authorities as an additional mitigation strategy for in-person schools in areas with high community transmission. This study aimed to evaluate the effectiveness and acceptance of different school-based SARS-CoV-2 testing strategies among students and staff in St. Louis.
Trial design
This completed study, designated as Phase NA, enrolled 1390 participants to investigate strategies for managing COVID-19 in schools. The primary goal was to determine the most effective SARS-CoV-2 testing strategy for a successful return to in-person school in underserved communities. The trial compared two distinct school-based testing strategies: symptomatic testing only versus weekly surveillance testing plus symptomatic testing. The study measured school-based SARS-CoV-2 transmission as a key outcome.
Key results
The trial reported the overall rate of all COVID-19 cases in schools under both testing strategies:
- For the group employing Weekly Screening Testing Plus Symptomatic Testing, there were 453 completed tests.
- For the group employing Symptomatic Testing alone, there were 297 completed tests.
A key analysis using generalized estimating equations showed a mean difference (final values) of -0.01845, with a 95.0% confidence interval ranging from -0.04981 to 0.01292. The p-value for this analysis was 0.25, indicating no statistically significant difference between the two testing strategies.
What this means
The findings suggest that, in the context of this study, adding weekly surveillance testing to symptomatic testing did not significantly reduce the overall rate of COVID-19 cases in K-12 schools compared to symptomatic testing alone. This outcome, with a p-value of 0.25, indicates that the observed differences were not statistically significant. These results may inform public health decisions regarding the allocation of resources and the implementation of COVID-19 testing protocols in school settings, particularly in underserved populations.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04875520, titled "Assessing Testing Strategies for Safe Return to K-12 Schools in an Underserved Population", were posted on 2025-07-04 on clinicaltrials.gov.